SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
|ClinicalTrials.gov Identifier: NCT00006361|
Recruitment Status : Completed
First Posted : May 30, 2003
Last Update Posted : December 4, 2009
RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor.
PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma of Unknown Primary Head and Neck Cancer Non-melanomatous Skin Cancer||Drug: semaxanib||Phase 2|
- Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck.
- Determine the safety and toxicity of SU5416 in these patients.
OUTLINE: Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed for 1 year.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1.4 years.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck|
|Study Start Date :||December 2000|
|Actual Primary Completion Date :||January 2003|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006361
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||David G. Pfister, MD||Memorial Sloan Kettering Cancer Center|